Bonum Therapeutics: Funding, Investors & Team (Sep 2026)
Allosteric regulation is a well-established technology that Bonum Therapeutics is concentrating on using to produce targeted, highly active, and less toxic medications.
Bonum Therapeutics has raised $120M across 2 funding rounds on record, the most recent an undisclosed round of $26.9M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Bonum Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Bonum Therapeutics Funding Rounds
Bonum Therapeutics raised $93.0M in a Series A announced in Nov 2022.
3.4 years later, an undisclosed round of $26.9M was announced in Apr 2026.
Bonum Therapeutics Founders and Leadership Team
Contact details for the Bonum Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Bonum Therapeutics Funding Compared to Other Biotechnology Startups
Bonum Therapeutics' latest round of $26.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Bonum Therapeutics in Biotechnology and Seattle
Companies Similar to Bonum Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Bonum Therapeutics Funding FAQs
What does Bonum Therapeutics do?
Allosteric regulation is a well-established technology that Bonum Therapeutics is concentrating on using to produce targeted, highly active, and less toxic medications.
How much funding has Bonum Therapeutics raised?
Bonum Therapeutics has raised $120M across 2 rounds on record. The most recent is an undisclosed round of $26.9M announced in Apr 2026.
When did Bonum Therapeutics last raise funding?
Bonum Therapeutics' most recent funding round on record is an undisclosed round of $26.9M, announced in Apr 2026.
Who is the CEO of Bonum Therapeutics?
John Mulligan is listed as CEO at Bonum Therapeutics.
Where is Bonum Therapeutics headquartered?
Bonum Therapeutics is based in Seattle, Washington, United States.
How many employees does Bonum Therapeutics have?
Bonum Therapeutics is in the 11-50 employee band.
How does Bonum Therapeutics' funding compare to other Biotechnology startups?
Bonum Therapeutics' latest round of $26.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Bonum Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Bonum Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.